Status:
COMPLETED
Relative Bioavailability of Olodaterol and Fluconazole
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
21-50 years
Phase:
PHASE1
Brief Summary
This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy male and female volunteers
Exclusion
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01153724
Start Date
May 1 2010
Last Update
June 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1222.48.1 Boehringer Ingelheim Investigational Site
Berlin, Germany